P10 pill pharmacology
Pro Research Analysisby 
Searched over 200M research papers
CT-P10 Pill Pharmacology: Mechanism, Pharmacokinetics, and Clinical Profile
CT-P10 Biosimilar Overview and Mechanism of Action
CT-P10 is a biosimilar to rituximab, a monoclonal antibody that targets the CD20 antigen on B cells. This mechanism is crucial for treating diseases like rheumatoid arthritis (RA), non-Hodgkin’s lymphoma (NHL), and chronic lymphocytic leukemia (CLL), as it leads to the depletion of B cells involved in these conditions 147. CT-P10 has an identical amino acid sequence and highly similar physicochemical and functional properties to the original rituximab .
Pharmacokinetics of CT-P10
Multiple studies have shown that CT-P10 and reference rituximab have equivalent pharmacokinetic profiles. Key pharmacokinetic parameters, such as area under the serum concentration–time curve (AUC) and maximum serum concentration (Cmax), consistently fall within the accepted bioequivalence range of 80% to 125% 3567. This equivalence has been demonstrated in patients with RA and advanced-stage follicular lymphoma, both as monotherapy and in combination with chemotherapy regimens like cyclophosphamide, vincristine, and prednisone (CVP) 56.
Efficacy and Safety Profile
CT-P10 has shown equivalent efficacy to rituximab in reducing disease activity in RA and achieving response rates in follicular lymphoma 357. The safety and immunogenicity profiles are also highly similar, with comparable rates of adverse events, serious adverse events, and the development of anti-drug antibodies 34567. The most common adverse events are consistent with those seen with rituximab, such as neutropenia and infusion-related reactions 56.
Clinical and Economic Implications
The introduction of CT-P10 as a biosimilar offers a cost-effective alternative to rituximab, potentially increasing patient access to treatment and reducing the economic burden on healthcare systems 14. CT-P10 is approved for all indications held by rituximab in several regions, including Europe and South Korea .
Special Note: P10 Peptide in Antiviral Research
It is important to distinguish CT-P10 from the P10 peptide referenced in antiviral research. The P10 peptide, when fused with elastin-like polypeptide (ELP), has shown promise as an antiviral agent against cytomegalovirus (CMV) by targeting viral protein interactions. However, this P10 peptide is unrelated to the CT-P10 biosimilar used in oncology and rheumatology .
Conclusion
CT-P10 is a biosimilar to rituximab with equivalent pharmacokinetics, efficacy, safety, and immunogenicity in the treatment of RA and certain lymphomas. Its introduction may improve access to biologic therapies and reduce treatment costs, while maintaining the clinical benefits of the original rituximab 134567. The P10 peptide in antiviral research is a separate entity and not related to CT-P10.
Sources and full results
Most relevant research papers on this topic